摘要
目的综合评价缬沙坦与卡托普利治疗原发性高血压和慢性心力衰竭的临床疗效,为临床合理用药提供循证依据。方法利用计算机对Pubmed、Web of Science、EMbase、CBM、万方数字化期刊全文库、中国期刊全文数据库、维普等数据库对有关缬沙坦与卡托普利治疗原发性高血压和慢性心力衰竭临床疗效的随机对照试验进行全面检索,检索时限为从建库至2017年7月,根据文献纳入与排除标准对所有文献进行独立筛选试验、提取资料、方法学质量评价等,然后进行统计分组后采用Rev Man 5.0软件对筛选后的文献进行统计分析。结果缬沙坦降低原发性高血压患者收缩压的效果更明显,差异有统计学意义[WMD=-1.63(95%CI,-3.71~0.27),P<0.05]。缬沙坦治疗慢性心力衰竭后左室射血分数、左室舒张末期容积明显优于卡托普利,差异有统计学意义[WMD=3.27(95%CI,0.81~5.49),P<0.05]。结论缬沙坦在调节原发性高血压收缩压、慢性心力衰竭左室射血分数、左室舒张末期容积上明显优于卡托普利,可作为临床治疗原发性高血压和慢性心力衰竭的首选药之一。
Objective To evaluate the clinical efficacy of valsartan and captopril in the treatment of primary hypertension and chronic heart failure,and provide evidence-based evidence for clinical rational use of drugs.Methods A comprehensive search for randomized controlled trials of Pubmed,Web of Science,EMbase,CBM,Wanfang digital periodical full-text database,Chinese Journal Full-text Database,VIP database of valsartan and Kato Pury in treatment of essential hypertension and chronic heart failure clinical curative effect was made by computer.The time limit for the retrieval was from the construction to the July 2017.According to the literature inclusion and exclusion criteria,the independent screening tests,data extraction and methodological quality evaluation of all literatures were carried out.After that,the statistical data were collected and analyzed by RevMan 5.0 software.Results The effect of valsartan on reducing the systolic pressure in patients with essential hypertension was more obvious,the difference was statistically significant[WMD=-1.63(95%CI,-3.71-0.27),P<0.05].After treatment,the left ventricular ejection fraction and left ventricular end diastolic volume were significantly better than those of captopril in the treatment of chronic heart failure.The difference was statistically significant([WMD=3.27,95%CI(0.81-5.49),P<0.05].Conclusion Valsartan is superior to captopril in regulating essential hypertension systolic blood pressure,chronic heart failure,left ventricular ejection fraction and left ventricular end diastolic volume.It can be used as one of the first choice for clinical treatment of essential hypertension and chronic heart failure.
作者
朱映华
ZHU Yinghua(Ciyun Hospital of Jieyang,Guangdong Province,Jieyang 522000,China)
出处
《中国医药科学》
2018年第5期44-46,50,共4页
China Medicine And Pharmacy
